Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
HeNan Splendor Science & Technology Co Ltd
SZSE:002296
|
CN |
|
Centrex Ltd
ASX:CXM
|
AU |
|
D
|
Dong Ah Tire & Rubber Co Ltd
KRX:282690
|
KR |
|
3M Co
NYSE:MMM
|
US |
|
M. J. International Co Ltd
TWSE:8466
|
TW |
|
H
|
Hold-Key Electric Wire & Cable Co Ltd
TWSE:1618
|
TW |
|
Eat & Beyond Global Holdings Inc
OTC:DGTEF
|
CA |
|
A
|
Archit Organosys Ltd
BSE:524640
|
IN |
|
Northwest Copper Corp
XTSX:NWST
|
CA |
|
A
|
Alviva Holdings Ltd
XBER:PNA
|
ZA |
|
H
|
Hamelin Gold Ltd
ASX:HMG
|
AU |
Biotron Ltd
Other Items
Biotron Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Other Items
AU$111.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Items
-$58k
|
CAGR 3-Years
23%
|
CAGR 5-Years
44%
|
CAGR 10-Years
4%
|
|
|
CSL Ltd
ASX:CSL
|
Other Items
-$15m
|
CAGR 3-Years
89%
|
CAGR 5-Years
5%
|
CAGR 10-Years
25%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Other Items
AU$500
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Items
-AU$229.9m
|
CAGR 3-Years
-384%
|
CAGR 5-Years
-213%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Other Items?
Other Items
111.5k
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's Other Items amounts to 111.5k AUD.
